within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H02A_CorticosteroidsForSystemicUsePlain.H02AB02_Dexamethasone;

model Dexamethasone_1
  extends Pharmacolibrary.Drugs.ATC.H.H02AB02_1;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>H02AB02_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dexamethasone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressant properties. It is used in the treatment of a variety of conditions, including autoimmune disorders, allergies, certain cancers, cerebral edema, and is commonly employed in the management of severe COVID-19 and as adjunctive therapy in chemotherapy-induced nausea. Dexamethasone is an approved drug and remains in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for intravenous administration of dexamethasone in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Czock, D, et al., &amp; Häussler, U (2005). Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clinical pharmacokinetics</i> 44(1) 61–98. DOI:<a href=\"https://doi.org/10.2165/00003088-200544010-00003\">10.2165/00003088-200544010-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15634032/\">https://pubmed.ncbi.nlm.nih.gov/15634032</a></p></li><li><p>Nijstad, AL, et al., &amp; Zwaan, CM (2022). Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting. <i>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</i> 30(12) 9991–9999. DOI:<a href=\"https://doi.org/10.1007/s00520-022-07423-6\">10.1007/s00520-022-07423-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36287279/\">https://pubmed.ncbi.nlm.nih.gov/36287279</a></p></li><li><p>Valtari, A, et al., &amp; Amo, EMD (2024). Comprehensive ocular and systemic pharmacokinetics of dexamethasone after subconjunctival and intravenous injections in rabbits. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 198 114260–None. DOI:<a href=\"https://doi.org/10.1016/j.ejpb.2024.114260\">10.1016/j.ejpb.2024.114260</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38484852/\">https://pubmed.ncbi.nlm.nih.gov/38484852</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dexamethasone_1;
